EHC Encompass Health Corp Insider Trading

CFO Douglas E Coltharp sells 27,694 shares at $106.83 for $2,958,550.47; retains 69,377 shares in EHC.

Douglas E Coltharp, EVP & Chief Financial Officer of Encompass Health Corp, executed 2 separate sales totaling 27,694 shares for $2,958,550.47 at a blended average price of $106.83. The reduction represents a -28.5% decrease in his holdings, leaving him with 69,377 shares post-transaction. The current stock price of $106.96 is -16.4% from the 52-week high of $127.99, and over his prior 5 trades at EHC, 3 of 5 same-ticker sells were well-timed (negative 90-day returns), though the most recent April 2025 tranche showed mixed near-term results (+3.1% to +4.6% at 30 days) before declining at the 90-day horizon. With the company reporting $1.6B in quarterly revenue, +10.5% annual growth, and a P/E of 17.42, the fundamentals remain intact, though the significant share reduction warrants monitoring of his forward outlook.

EHC treasurer Fay Edmund sold 11,937 shares at $107.00; stock now $106.89, -16.0% from 52-week high of $127.18

Fay Edmund, Sr. Vice President and Treasurer of Encompass Health Corp, executed a sale of 11,937 shares at $107.00 on March 9, 2026, reducing his holdings from 98,262 shares to 86,325 shares—a -12.1% reduction in his position. The sale occurred near the current market price of $106.89, but notably below the 52-week high of $127.18, representing a -16.0% discount from peak valuation. While the company's fundamentals remain solid (10.5% annual revenue growth, P/E of 16.32, and $1.5B quarterly revenue), this transaction reduces senior-level ownership at a point where the stock has declined substantially from its recent high. The 30-day and 90-day price changes remain modestly positive (+1.4% and +0.5%), suggesting a general stability in the near term despite the recent peak retreat.

CEO Mark J Tarr sells 150,000 shares at $111.64 avg for $16.7M on 2026-02-11 (-28.5% of holdings)

Mark J Tarr, President & CEO of Encompass Health Corp, executed 7 separate sales totaling 150,000 shares (150.0K shares) for $16,746,688.16 ($16.7M) on 2026-02-11, reducing his holdings by 28.5% to 377.1K shares. The blended average sale price of $111.64 sits 0.4% above the current price of $112.06 and -11.9% below the 52-week high of $127.18, indicating sales executed near recent highs but ahead of a 12-month pullback. His cross-ticker track record shows a 75.00% well-timed rate on 4 prior sells with an average 90-day return of -0.2%, and at EHC specifically, 3 of 4 prior sells occurred before or during downward periods (90-day returns of -1.0%, -1.5%, and -9.0% on three of those trades). The company's fundamentals remain solid with FY revenue growth of +11.9%, P/E of 20.83, and $1.5B quarterly revenue, though the magnitude of this sale—the largest proportion of holdings liquidated by this executive in recent filings—warrants close observation of market sentiment and third-quarter guidance.

EHC CEO Mark Tarr sells 118,384 shares for $14,387,152.06; holdings drop 18.3% post-transaction

Mark Tarr, President & CEO of Encompass Health Corp, executed two separate sales on 2025-05-20 totaling 118,384 shares (118.4K shares) for $14,387,152.06 ($14.4M) at a blended average price of $121.53, reducing his post-transaction holdings to 527,070 shares (527.1K shares) from 645,454 shares (645.5K shares)—a net reduction of 18.3% of pre-transaction holdings. The sale occurred at the 52-week high price of $121.73 (current price), with the stock up 17.8% over the prior 30 days and 19.8% over the prior 90 days, following recent strong momentum. Examining Tarr's cross-ticker track record, his 2 prior open-market sells averaged -0.8% 30-day return and +0.4% 90-day return with a 50.00% well-timed rate, indicating his sell timing has been mixed historically; at EHC specifically, his prior 2 sales showed divergent timing outcomes (2024 sale: +2.8% / +9.9% at 30/90 days; 2023 sale: -4.4% / -9.0% at 30/90 days). The company's fundamentals remain solid with $1.5B in latest quarterly revenue, $151.5M net income, 11.9% annual revenue growth, and a P/E of 24.79, with a market cap of $12.3B. The significance of this trade lies in the substantial dollar value and the percentage of holdings divested during a period of elevated stock momentum, warranting investor attention to the magnitude and timing context.

EHC EVP & Gen Counsel Darby John Patrick sold 10,000 shares at $114.79; stock at $116.99, +15.5% in 30 days.

Darby John Patrick sold 10,000 shares (approximately 11.1% reduction in holdings) at $114.79 on 2025-04-29, leaving him with 79,710 shares. The sale occurred while EHC traded at a 52-week high of $116.99, and the stock has gained 15.5% over the past 30 days and 18.9% over 90 days, indicating strong recent momentum. His prior sell at this ticker on 2024-05-06 showed a 90-day return of 10.4%, meaning the stock rose significantly after that sale—a poorly-timed outcome for a seller. This current sale follows the same pattern: the stock is near its highs, recent performance has been strong, and his cross-ticker selling track record shows a 0.00% well-timed rate across one prior sale. The transaction merits standard monitoring but lacks evidence of forward-looking conviction based on historical patterns.

CFO Coltharp sells 43,575 shares of EHC for $5,017,537.68, reducing holdings 41.9%, near 52-week high of $116.99

CFO Douglas Coltharp executed 3 separate sales on 2025-04-29, selling a total of 43,575 shares (43.6K shares) at prices ranging from $114.78 to $116.36 (blended average $115.15) for $5,017,537.68 ($5.0M), reducing his holdings by 41.9% from 103,910 to 60,335 shares. The sales occurred at prices near the stock's 52-week high of $116.99, with the current price at that level. His prior two measurable sales at EHC (2024-08-13) produced 90-day returns of +19.6% and +18.7%, indicating the stock rose after those sales—a poorly-timed outcome by the 0 of 2 well-timed rate metric. The company shows solid fundamentals with annual revenue growth of +11.9% and a P/E of 22.41, though the stock has appreciated +15.5% over the past 30 days and +18.9% over 90 days, reflecting strong recent momentum at the time of this substantial equity reduction.

CFO Coltharp sells 12,260 shares of EHC at $86.34 blended price for $1.1M; prior EHC sale in Nov 2023 saw 90-day stock rise

Douglas E. Coltharp, EVP & Chief Financial Officer, executed 2 separate sales totaling 12,260 shares on 2024-08-13 for $1,058,474.40 at a blended average price of $86.34, reducing his holdings from 148,487 to 136,227 shares (an 8.3% reduction). At the same-ticker level, his only prior EHC trade was a sale on 2023-11-13, which was followed by a 90-day return of +15.0%, meaning the stock rose after that insider sale rather than fell. The current stock price of $86.98 sits 6.5% below the 52-week high of $93.02, with the company posting strong recent fundamentals (FY revenue growth of +10.4%, P/E of 21.91). The timing pattern at EHC offers no signal of predictive accuracy: his 1 prior sale at this ticker resulted in a gain for equity holders, not a loss that would suggest prescient insider selling.